SAM SAFAEE: Open Payments
NPI 1609172030 · SANTA MARIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$654 in 30 payments from 9 companies in 2025. Trend: 2023 $84 · 2024 $294 · 2025 $654
Food & beverage: $654
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $190 |
| Sumitomo Pharma America, Inc. | 1 | $111 |
| Tris Pharma Inc | 2 | $93 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| Supernus Pharmaceuticals, Inc. | 2 | $66 |
| Alkermes, Inc. | 2 | $56 |
| Lundbeck LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $21 |
Products named: VRAYLAR, GEMTESA, Dyanavel XR, FANAPT, Qelbree, ARISTADA, ABILIFY ASIMTUFII, LOREEV XR.
Industry payments across CA — which companies pay providers there.
